Information Provided By:
Fly News Breaks for October 18, 2018
NVS, ECYT
Oct 18, 2018 | 10:50 EDT
Wedbush analyst David Nierengarten downgraded Endocyte (ECYT) to Neutral after the company agreed to be acquired by Novartis (NVS) for $24 per share. The analyst does not next another bidder to emerge.
News For ECYT;NVS From the Last 2 Days
There are no results for your query ECYT;NVS